Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that final Phase 2 data for
perifosine, its oral AKT inhibitor, combined with sorafenib in patients
with relapsed/refractory lymphomas, will be presented at the upcoming
American Society of Hematology ("ASH") annual meeting in Atlanta,
Georgia, December 8-11, 2012. Data will be disclosed during a poster
presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy.
"Dual Targeted Therapy with the AKT Inhibitor Perifosine and the
Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory
Lymphomas: Final Results of a Phase 2 Trial", A Guidetti, S. Viviani, A. Marchiano, A. Dodero, L. Farina, S.L.
Locatelli, D. Russo, P. Bulian, R. Sorasio, M. Di Nicola, L. Giordano,
P. Corradini, A.M. Gianni, C. Carlo-Stella.
Poster Session #624:
"Lymphoma-Therapy with Biologic Agents, Excluding Pre-Clinical Models:
Date & Time:
Monday, December 10, 2012, from 6 pm to 8 pm (Eastern)
Georgia World Congress Center, Hall B1-B2, Level 1, Building B
Perifosine is a novel, oral anticancer treatment that inhibits Akt
activation in the phosphoinositide 3-kinase (PI3K) pathway. It has been
granted orphan drug and orphan medicinal product designations for
multiple myeloma ("MM") from the FDA and the European Medicines Agency
("EMA"), respectively. Perifosine